SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around the long-standing joke and the coin's presence on the Solana network. Community members are actively engaging in the 'What's UpDog?' meme, celebrating its resilience and unique place as the only UPDOG on the Jupiter Strict List.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential revenue generation and real-world asset (RWA) adoption. Some users are speculating on partnerships and integrations with other projects. Bullish sentiment is fueled by discussions of on-chain matrix rewards and treasury mechanics.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending as an AI meme coin linked to Elon Musk's Grok, sparking community excitement. The "Byte Army" is actively promoting the token, emphasizing its community-owned nature and potential in the AI and meme coin sectors. Discussions also highlight whale accumulation and positive sentiment from LunarCrush.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss its partnerships with major tech companies like AMD and Nvidia, particularly regarding QNX's role in automotive and robotics. Community members are highlighting the company's potential for growth and a possible breakout, fueled by anticipation for upcoming earnings. The conversation also includes discussions around technical analysis, market manipulation, and BlackBerry's long-term prospects as a software and cybersecurity player.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Enthusiastic community members are actively promoting $CAW.X, a memecoin known as "crow with knife", across various chains. The community emphasizes its deflationary nature and strong social presence, encouraging others to join and "caw caw" their way to potential gains. Mentions of "layer zero burn mechanism in place" and "crow with knife is the only option" highlight key community talking points.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its recent listing on Bifinance, generating excitement about increased liquidity and exposure. The community emphasizes its consistent 'grind,' utility development, and active developer, setting it apart from other meme coins. Many express bullish sentiment and highlight the project's commitment to delivering on promises, with some mentioning an upcoming burn event.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics is trending due to positive Phase 2 trial results for their hidradenitis suppurativa treatment, sonelokimab, which has sparked considerable excitement and discussion within the biotech community. Community members are actively debating the potential for a buyout, comparing the company's prospects to competitors, and analyzing the implications of a possible public offering. The stock's movement is also influenced by discussions about short squeezes and technical indicators.

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

ResMed ($RMD) is trending due to speculation around a potential partnership or acquisition with Incannex ($IXHL), fueled by positive Phase 2 results for Incannex's sleep apnea pill and a ResMed advisor on Incannex's clinical advisory board. Community members are discussing the strategic implications of a potential deal, with some suggesting it could revolutionize sleep apnea treatment. The community highlights the potential for a significant market impact should Incannex and ResMed collaborate.

The centrifuge token model powers centrifuge, providing the framework needed to run the platform without reliance on a single point of failure, including the centrifuge team or Company, and to accelerate its utility. To accomplish this, centrifuge leverages the cryptoeconomic primitives of a native token called the centrifuge token (cfg), a nominated-proof-of-stake consensus algorithm that employs centrifuge to stake value, rewards for centrifuge adoption, and an on-chain governance mechanism that empowers centrifuge holders to guide the development of centrifuge.

Centrifuge

Centrifuge ($CFG.X) is gaining attention, fueled by its focus on Real World Assets (RWAs) and recent integrations that facilitate easier tokenization and DeFi utilization. Community members highlight its potential to bridge traditional finance with DeFi, pointing to partnerships and new asset onboarding processes as catalysts. Discussions also revolve around technical analysis, potential price targets, and the impact of broader market trends.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea (LINEA.X) is trending as the community discusses its potential integration with SWIFT, a global banking network. Many see this as a major development for the Ethereum ecosystem and a possible challenge to existing cross-border payment solutions. Some community members are suggesting LINEA.X as an alternative to XRP, highlighting the SWIFT narrative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 0.00% and +14.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy?

Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered into a licensing deal with Biosion for rights for two antibody products and announced an $80 million funding, lifting retail sentiment.Aclaris is focused on developing drugs to treat immuno-inflammatory diseases. The exclusive license agreement with Biosion includes worldwide rights (excluding Greater China) to BSI-045B, a clinical-stage, novel anti-TSLP monoclonal antibody; and BSI-502, a pre-clinical stage novel bispecific antibody directed against “both TSLP and IL4R,” used to treat conditions like atopic dermatitis. &nbsp;The private placement includes over 35.55 million shares of common stock at a purchase price of $2.25 per share. The placement is expected to close on or about Nov. 19, 2024, subject to customary closing conditions.Vivo Capital led the funding, with participation from new and existing investors including Forge Life Science Partners, Rock Springs Capital, RA Capital Management, Adage Capital Partners LP, Decheng Capital, Logos Capital and Samsara BioCapital.Several brokerages have revised their ratings for Aclaris following the news. Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2. The firm cited completion of the company's strategic review, and expects investor focus to shift to its "newly strengthened" immunology-focused pipeline that includes the two in-licensed biologics from discovery-focused Biosion - BSI-045B and BSI-502, The Fly.com <a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/">reported.</a>Jefferies also upgraded Aclaris to ‘Buy’ from ‘Hold’ with a price target of $7, up from $2.Meanwhile, Piper Sandler upgraded the company to ‘Overweight’ from ‘Neutral’ with a price target of $13, up from $3.Retail sentiment moved from ‘neutral’ (47/100) to ‘extremely bullish’(96/100); message volumes rose to ‘extremely high’ levels from ‘normal’.<figure class="image"><img style="aspect-ratio:1304/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_19_at_9_24_37_PM_b73837e53c.png" alt="Screenshot 2024-11-19 at 9.24.37 PM.png" width="1304" height="290"><figcaption>ACRS sentiment and message volumes on Nov 19 as of 10:55 am ET| Source: Stocktwits</figcaption></figure>“This transformative transaction, which marks the completion of our strategic review process, accelerates our evolution into becoming a leading immunology company with both small and large molecule drugs," Neal Walker, interim CEO and chair of Aclaris, said in a statement.Net proceeds from the capital raise are expected to fund the research and development of its drug pipeline and for general corporate purposes.Aclaris stock is up 300% year-to-date.For updates and corrections, email newsroom@stocktwits.com &nbsp;&nbsp;

Net proceeds from the capital raise are expected to fund the research and development of its drug pipeline| Picture source: pexels

Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps

Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2; Piper Sandler upgraded the company  to ‘Overweight’ from ‘Neutral.’ 

Equity

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets Biosion Announces Exclusive, Global License...

H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Aclaris Therapeutics (ACRS Research Report). The compa...

Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties

Aclaris Therapeutics (ACRS) has provided an update. Aclaris Therapeutics has struck a lucrative deal with OMERS, selling a portion of its future ro...

Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Aclaris Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

ACRS
Aclaris Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ACRS News

ACRS Aclaris Therapeutics Inc